MCID: PHC019
MIFTS: 36

Pheochromocytoma-Paraganglioma

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Pheochromocytoma-Paraganglioma

MalaCards integrated aliases for Pheochromocytoma-Paraganglioma:

Name: Pheochromocytoma-Paraganglioma 58 29

Classifications:



External Ids:

Orphanet 58 ORPHA573163

Summaries for Pheochromocytoma-Paraganglioma

MalaCards based summary : Pheochromocytoma-Paraganglioma is related to hereditary paraganglioma-pheochromocytoma syndromes and malignant pheochromocytoma. An important gene associated with Pheochromocytoma-Paraganglioma is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Pathways in cancer and Carbon metabolism. The drugs Doxazosin and Phenoxybenzamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, testes and thyroid, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pheochromocytoma-Paraganglioma

Diseases in the Pheochromocytoma-Paraganglioma family:

Hereditary Paraganglioma-Pheochromocytoma Syndromes

Diseases related to Pheochromocytoma-Paraganglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 hereditary paraganglioma-pheochromocytoma syndromes 31.2 VHL TMEM127 SDHD SDHC SDHB SDHA
2 malignant pheochromocytoma 30.8 SDHB PNMT
3 foster-kennedy syndrome 30.4 SDHD SDHA
4 neurofibromatosis 30.3 VHL SDHD SDHB RET
5 multiple endocrine neoplasia 30.3 VHL SDHC SDHB RET
6 neuroendocrine tumor 29.9 VHL SDHD SDHB RET
7 ganglioneuroma 29.9 RET PNMT
8 polycythemia 29.9 VHL EGLN2 EGLN1
9 paragangliomas 1 29.8 SDHD SDHC SDHB RET
10 mitochondrial complex ii deficiency 29.8 SDHD SDHC SDHB SDHA
11 leigh syndrome 29.7 SDHD SDHC SDHB SDHA
12 hypoxia 29.6 VHL EGLN2 EGLN1
13 kidney cancer 29.1 VHL SDHB HIF1A-AS2
14 extra-adrenal pheochromocytoma 28.5 TMEM127 SDHD SDHC SDHB SDHA RET
15 renal cell carcinoma, nonpapillary 28.5 VHL SDHC SDHB RET HIF1A-AS2 EGLN1
16 paraganglioma 28.3 VHL TMEM127 SDHD SDHC SDHB SDHA
17 multiple endocrine neoplasia, type iia 28.2 VHL TMEM127 SDHD SDHC SDHB SDHA
18 von hippel-lindau syndrome 28.0 VHL TMEM127 SDHD SDHC SDHB RET
19 pheochromocytoma 27.8 VHL TMEM127 SDHD SDHC SDHB SDHA
20 adrenal gland pheochromocytoma 11.1
21 adenoma 10.4
22 pituitary adenoma 10.4
23 thyroid carcinoma 10.4
24 neuroblastoma 10.3
25 glomus tumor 10.2 SDHD SDHB
26 paragangliomas 4 10.2
27 thyroid cancer, nonmedullary, 1 10.2
28 heart disease 10.2
29 gangliocytoma 10.2
30 lymphopenia 10.2
31 pituitary tumors 10.2
32 b-lymphoblastic leukemia/lymphoma with hypodiploidy 10.2 SDHA RET
33 spastic paraplegia 38, autosomal dominant 10.2 SDHB SDHA
34 hereditary renal cell carcinoma 10.2 SDHB SDHA
35 spastic quadriplegia 10.1 SDHD SDHA
36 quadriplegia 10.1 SDHD SDHA
37 carney complex variant 10.1 SDHD RET
38 cardiac arrhythmia 10.0
39 fibromuscular dysplasia 10.0
40 thyroid carcinoma, familial medullary 10.0
41 3-methylglutaconic aciduria, type iii 10.0
42 pituitary adenoma, prolactin-secreting 10.0
43 paragangliomas 2 10.0
44 paragangliomas 5 10.0
45 tumor predisposition syndrome 10.0
46 familial adenomatous polyposis 10.0
47 desmoid tumor 10.0
48 hypogonadotropic hypogonadism 10.0
49 allergic hypersensitivity disease 10.0
50 hemosiderosis 10.0

Graphical network of the top 20 diseases related to Pheochromocytoma-Paraganglioma:



Diseases related to Pheochromocytoma-Paraganglioma

Symptoms & Phenotypes for Pheochromocytoma-Paraganglioma

GenomeRNAi Phenotypes related to Pheochromocytoma-Paraganglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.32 RET
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.32 RET
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-164 9.32 RET
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.32 SDHC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.32 SDHC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-192 9.32 EGLN2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-24 9.32 EGLN2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.32 RET
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 9.32 SDHC
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-82 9.32 EGLN2

MGI Mouse Phenotypes related to Pheochromocytoma-Paraganglioma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.86 EGLN1 EGLN2 RET SDHB SDHC SDHD
2 homeostasis/metabolism MP:0005376 9.85 EGLN1 EGLN2 PNMT RET SDHA SDHB
3 muscle MP:0005369 9.35 EGLN1 EGLN2 RET SDHC VHL
4 neoplasm MP:0002006 9.02 RET SDHB SDHC SDHD VHL

Drugs & Therapeutics for Pheochromocytoma-Paraganglioma

Drugs for Pheochromocytoma-Paraganglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxazosin Approved Phase 3 74191-85-8 3157
2
Phenoxybenzamine Approved Phase 3 59-96-1 4768
3 Adrenergic alpha-Antagonists Phase 3
4 Antihypertensive Agents Phase 3
5 Adrenergic Antagonists Phase 3
6 Adrenergic Agents Phase 3
7 Vasodilator Agents Phase 3
8 Adrenergic alpha-1 Receptor Antagonists Phase 3
9
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
10
Pembrolizumab Approved Phase 2 1374853-91-4
11
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
12
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
13
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
14
Lenvatinib Approved, Investigational Phase 2 417716-92-8
15
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
16
Epinephrine Approved, Vet_approved Phase 1, Phase 2 51-43-4 5816
17
nivolumab Approved Phase 1, Phase 2 946414-94-4
18
Racepinephrine Approved Phase 1, Phase 2 329-65-7 838
19
lanreotide Approved Phase 2 108736-35-2
20
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
21
Olaparib Approved Phase 2 763113-22-0 23725625
22
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
23
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
24 Guadecitabine Investigational Phase 2 929901-49-5
25 Immunosuppressive Agents Phase 2
26 Immunologic Factors Phase 2
27 Pharmaceutical Solutions Phase 2
28 Fluorodeoxyglucose F18 Phase 2
29 Antineoplastic Agents, Immunological Phase 2
30 Antineoplastic Agents, Hormonal Phase 2
31 Gastrointestinal Agents Phase 2
32 Protein Kinase Inhibitors Phase 2
33 Angiogenesis Inhibitors Phase 2
34 Edotreotide Phase 2
35 Radiopharmaceuticals Phase 2
36 Vaccines Phase 1, Phase 2
37 Epinephryl borate Phase 1, Phase 2
38 Angiopeptin Phase 2
39 Alkylating Agents Phase 2
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
41
Dopamine Approved 51-61-6, 62-31-7 681
42 3-Iodobenzylguanidine
43 Dihydroxyphenylalanine
44 Trace Elements
45 Anti-Infective Agents
46 Anti-Infective Agents, Local
47 Nutrients
48 Micronutrients
49 Neurotransmitter Agents
50 Dopamine Agents

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
2 Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma Recruiting NCT03176693 Phase 3 Phenoxybenzamine;Doxazosin
3 A Phase I Study Evaluating the Maximum Tolerated Dose, Dosimetry, Safety, and Efficacy of Ultratrace Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Completed NCT00458952 Phase 1, Phase 2 Ultratrace Iobenguane (MIBG) I 131
4 A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma Completed NCT01635907 Phase 2 Dovitinib
5 A Phase II Study of 131I-labeled Metaiodobenzylguanidine (MIBG) for Treatment of Patients With Metastatic or Unresectable Pheochromocytoma and Related Tumors Completed NCT01413503 Phase 2
6 Phase II Study of RAD001monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid Completed NCT01152827 Phase 2 RAD001
7 A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer Completed NCT03165721 Phase 2 SGI-110 (guadecitabine)
8 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Recruiting NCT03839498 Phase 2 Axitinib
9 Phase 2 Study of ONC201 in Neuroendocrine Tumors Recruiting NCT03034200 Phase 2 ONC201
10 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Recruiting NCT01371201 Phase 2 Sunitinib;Placebo
11 A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas Recruiting NCT02302833 Phase 2 Cabozantinib S-malate
12 Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Recruiting NCT03206060 Phase 2 Lu-177-DOTATATE;Ga-68-DOTATATE;F-18-FDG;Amino Acid solution
13 Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Recruiting NCT02721732 Phase 2
14 Clinical Study of the Use of Yttrium-90 (90Y) and/or Lutecium-177 (177Lu) DOTATATE (DOTA-0-Tyr3-Octreotate) in the Treatment of Disseminated and / or Symptomatic Tumors With Somatostatin Receptor Overexpression Recruiting NCT04029428 Phase 2 90Y-DOTATATE;(177Lu-DOTAOTyr3)Octreotate;90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
15 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Active, not recruiting NCT01967576 Phase 2 Axitinib (AG-013736)
16 A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Active, not recruiting NCT00874614 Phase 2
17 Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma Active, not recruiting NCT03008369 Phase 2 Lenvatinib
18 A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma Active, not recruiting NCT00843037 Phase 2 Sunitinib
19 A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored, Study to Determine the Safety and Effectiveness of 177LuDOTATOC in Adult Subjects With STTR(+) Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus Neuroendocrine Tumors (PUTNET) Not yet recruiting NCT04276597 Phase 2 177Lu-DOTATOC
20 A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04187404 Phase 1, Phase 2
21 Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA) Not yet recruiting NCT03946527 Phase 2 Lanreotide
22 Phase I/II Trial of Peptide Receptor Radiotherapy (PRRT) With 177Lu-DOTA-tyr3 OCTREOTATE (177Lu-DOTATATE) in Children With Neuroendocrine Tumor, Neuroblastoma, or Pheochromocytoma/Paraganglioma Not yet recruiting NCT03923257 Phase 1, Phase 2 177Lu-DOTA-tyr3-OCTREOTATE
23 A Phase II Study to Evaluate the Effects of 177Lu-DOTATATE in Patients With Unresectable and Progressive Rare Metastatic Endocrine Carcinomas: Medullary Thyroid Cancer, Parathyroid Carcinoma, Pituitary Carcinoma, and Malignant Pheochromocytoma/Paraganglioma Not yet recruiting NCT04106843 Phase 2 Lutetium Lu 177 Dotatate
24 A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma Not yet recruiting NCT04394858 Phase 2 Olaparib;Temozolomide
25 Exploratory Basket Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. CABATEN Study Not yet recruiting NCT04400474 Phase 2 Cabozantinib 40 mg
26 A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma Terminated NCT01340794 Phase 2 Pazopanib Hydrochloride
27 Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid Completed NCT00339131 Phase 1 Ultratrace iobenguane I 131
28 A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma Withdrawn NCT01941849 Phase 1 Vandetanib
29 Performance of an Omics-signature in the Diagnosis and Prognosis of Endocrine and Primary Hypertension Unknown status NCT02772315
30 Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation: Monocentric Prospective Study Unknown status NCT02186678
31 Expanded Access Program of AZEDRA (Ultratrace Iobenguane I131) in Subjects With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma: A Sub-study of Protocol MIP-IB12B Approved for marketing NCT02961491 Ultratrace Iobenguane I131
32 Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma Approved for marketing NCT01377532 131 I-Metaiodobenzylguanidine (131 I-MIBG)
33 Evaluation Des méthodes de dépistage du Paragangliome héréditaire Chez Les Sujets prédisposés génétiquement Completed NCT00188019
34 Clinical Application of New Pheochromocytoma Markers: INSERM Pilot Study of the Specificity of Elevated Plasma EM66 Concentrations in Patients With Pheochromocytoma or Paraganglioma Compared to Patients With Essential Hypertension Completed NCT01022515
35 Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) Completed NCT02539433
36 The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card Completed NCT02672020
37 Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions Recruiting NCT03160274
38 The MUPPET-study: Multicenter Pheochromocytoma and Paraganglioma Evaluation for Follow-up Screening, Genetics Sub-Typing, Therapy and Outcome Recruiting NCT03344016
39 Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study Active, not recruiting NCT02592356 Cabozantinib;Lenvatinib
40 An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma (Not Eligible for Approved Treatment) Available NCT01590680
41 I-Metaiodobenzylguanidine (131 I-MIBG) Therapy for Refractory Neuroblastoma and Paraganglioma/Pheochromocytoma Expanded Access Protocol Available NCT01163383 131 I-Metaiodobenzylguanidine (131 I-MIBG);131 I-MIBG
42 An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Available NCT01838187
43 [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours Available NCT02431715 [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
44 Epidemiology of Pituitary Tumours: Prevalence of Associated Endocrine and Non-endocrine Tumours and Potential Implications in the Management and Follow-up of Patients" Not yet recruiting NCT03973450
45 Content Validation of the EORTC QLQ-C30 Version 3.0, and NIH Quality of Life and Symptoms Questionnaire for Pheochromocytoma and Paraganglioma Terminated NCT00911729

Search NIH Clinical Center for Pheochromocytoma-Paraganglioma

Genetic Tests for Pheochromocytoma-Paraganglioma

Genetic tests related to Pheochromocytoma-Paraganglioma:

# Genetic test Affiliating Genes
1 Pheochromocytoma-Paraganglioma 29

Anatomical Context for Pheochromocytoma-Paraganglioma

MalaCards organs/tissues related to Pheochromocytoma-Paraganglioma:

40
Pituitary, Testes, Thyroid, Thymus, Kidney, Heart, Lung

Publications for Pheochromocytoma-Paraganglioma

Articles related to Pheochromocytoma-Paraganglioma:

(show top 50) (show all 309)
# Title Authors PMID Year
1
Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion. 61
32521546 2020
2
Targeting Pheochromocytoma/Paraganglioma with polyamine inhibitors. 61
32562798 2020
3
A case report of rare ectopic pheochromocytoma adjacent to pancreas. 61
32569235 2020
4
MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression. 61
32511227 2020
5
A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats. 61
32252027 2020
6
Clinical factors affecting spot urine fractionated metanephrines in patients suspected pheochromocytoma/paraganglioma. 61
32020083 2020
7
Intraoperative hypotension is associated with increased postoperative complications in patients undergoing surgery for pheochromocytoma-paraganglioma: a retrospective cohort study. 61
32532209 2020
8
VHL-RELATED NEUROENDOCRINE NEOPLASMS AND BEYOND: AN ISRAELI SPECIALIZED CENTER REAL-LIFE REPORT. 61
32576040 2020
9
The Changing Paradigm of Head and Neck Paragangliomas: What Every Otolaryngologist Needs to Know. 61
32486832 2020
10
The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types. 61
32533054 2020
11
Identification of a novel SDHB c.563 T > C mutation responsible for Paraganglioma syndrome and genetic analysis of the SDHB gene in China: a case report. 61
32460727 2020
12
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin. 61
32205473 2020
13
Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. 61
32151355 2020
14
Cytochrome 450 metabolites of arachidonic acid (20-HETE, 11,12-EET and 14,15-EET) promote pheochromocytoma cell growth and tumor associated angiogenesis. 61
32105813 2020
15
Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas. 61
32299111 2020
16
Catecholamines Induce Trained Immunity In Monocytes In Vitro and In Vivo. 61
32241223 2020
17
Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. 61
32152203 2020
18
Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. 61
31614368 2020
19
Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing. 61
31978379 2020
20
Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service. 61
32207276 2020
21
Miction-induced Hypertension Disclosed by Home Blood Pressure Measurement in a Patient with Small Paraganglioma. 61
31813909 2020
22
Endocrine causes of hypertension in pregnancy. 61
32206600 2020
23
A Review of Catecholamine Associated Cardiomyopathies and Channelopathies. 61
32195067 2020
24
Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma/paraganglioma: retrospective single-center study. 61
32067697 2020
25
Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. 61
32206603 2020
26
Open surgery for pheochromocytoma: Current indications and outcomes from a retrospective cohort. 61
31983822 2020
27
Invasion of Pheochromocytoma from the Caudal Vena Cava to the Right Ventricular Cavity in a Dog. 61
32095312 2020
28
68Ga-DOTATATE positron emission tomography/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia. 61
32190030 2020
29
Identification of Genes Associated with the Metastasis of Pheochromocytoma/Paraganglioma Based on Weighted Gene Coexpression Network Analysis. 61
32090084 2020
30
Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature. 61
32132978 2020
31
Pheochromocytomas and Paragangliomas. 61
31655773 2019
32
Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. 61
31614337 2019
33
A primer on the genetics of medullary thyroid cancer. 61
31896937 2019
34
Correlation between urinary fractionated metanephrines in 24-hour and spot urine samples for evaluating the therapeutic effect of metyrosine: a subanalysis of a multicenter, open-label phase I/II study. 61
31511435 2019
35
Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. 61
31009053 2019
36
3P association (3PAs): Pituitary adenoma and pheochromocytoma/paraganglioma. A heterogeneous clinical syndrome associated with different gene mutations. 61
31431315 2019
37
Pheochromocytoma: Positive predictive values of mildly elevated urinary fractionated metanephrines in a large cohort of community-dwelling patients. 61
31486577 2019
38
Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. 61
31597347 2019
39
Seizures in patients with a phaeochromocytoma/paraganglioma (PPGL): A review of clinical cases and postulated pathological mechanisms. 61
31133278 2019
40
Imaging Features of Succinate Dehydrogenase-deficient Pheochromocytoma-Paraganglioma Syndromes. 61
31498738 2019
41
Addressing delays in the diagnosis of pheochromocytoma/paraganglioma. 61
31429343 2019
42
The role of an anti-diabetic drug metformin in the treatment of endocrine tumors. 61
31307011 2019
43
Two rare cases of paraganglioma in patients with Fontan physiology. 61
31284893 2019
44
SDHx-related pheochromocytoma/paraganglioma - genetic, clinical, and treatment outcomes in a series of 30 patients from a single center. 61
31104306 2019
45
Brown adipose activation and reversible beige coloration in adipose tissue with multiple accumulations of 18F-fluorodeoxyglucose in sporadic paraganglioma: A case report. 61
31360497 2019
46
Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder? 61
31367972 2019
47
COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas. 61
30868297 2019
48
Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. 61
31053249 2019
49
Performance of plasma free metanephrines in diagnosis of pheochromocytomas and paragangliomas in the population of Asturias. 61
30391255 2019
50
68Ga-DOTANOC PET/CT in an Atypical Extraskeletal Paravertebral Hemangioma Mimicking as Neurogenic Tumor in a Known Case of Breast Cancer. 61
30829863 2019

Variations for Pheochromocytoma-Paraganglioma

Expression for Pheochromocytoma-Paraganglioma

Search GEO for disease gene expression data for Pheochromocytoma-Paraganglioma.

Pathways for Pheochromocytoma-Paraganglioma

GO Terms for Pheochromocytoma-Paraganglioma

Cellular components related to Pheochromocytoma-Paraganglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial inner membrane GO:0005743 9.46 SDHD SDHC SDHB SDHA
2 respiratory chain complex II GO:0045273 8.96 SDHC SDHB
3 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.92 SDHD SDHC SDHB SDHA

Biological processes related to Pheochromocytoma-Paraganglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.63 SDHD SDHC SDHB SDHA EGLN2 EGLN1
2 electron transport chain GO:0022900 9.54 SDHC SDHB SDHA
3 aerobic respiration GO:0009060 9.46 SDHC SDHB
4 respiratory electron transport chain GO:0022904 9.43 SDHB SDHA
5 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.43 VHL EGLN2 EGLN1
6 peptidyl-proline hydroxylation to 4-hydroxy-L-proline GO:0018401 9.4 EGLN2 EGLN1
7 succinate metabolic process GO:0006105 9.32 SDHB SDHA
8 mitochondrial electron transport, succinate to ubiquinone GO:0006121 9.13 SDHD SDHC SDHA
9 tricarboxylic acid cycle GO:0006099 8.92 SDHD SDHC SDHB SDHA

Molecular functions related to Pheochromocytoma-Paraganglioma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.8 SDHB SDHA EGLN2 EGLN1
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.48 SDHC SDHA
3 ferrous iron binding GO:0008198 9.46 EGLN2 EGLN1
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors GO:0016706 9.43 EGLN2 EGLN1
5 L-ascorbic acid binding GO:0031418 9.4 EGLN2 EGLN1
6 ubiquinone binding GO:0048039 9.37 SDHD SDHB
7 peptidyl-proline dioxygenase activity GO:0031543 9.32 EGLN2 EGLN1
8 peptidyl-proline 4-dioxygenase activity GO:0031545 9.26 EGLN2 EGLN1
9 electron transfer activity GO:0009055 9.26 SDHD SDHC SDHB SDHA
10 succinate dehydrogenase (ubiquinone) activity GO:0008177 9.16 SDHB SDHA
11 succinate dehydrogenase activity GO:0000104 8.8 SDHD SDHC SDHA

Sources for Pheochromocytoma-Paraganglioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....